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Salivary and lacrimal gland dysfunction is relatively frequent after radioiodine therapy. In 
most cases this is a transient side effect, but in some patients it may persist for a long period 
or appear late. Radioiodine (¹³¹I) therapy is often administered to patients following total thy-
roidectomy to treat well-differentiated follicular cell-derived thyroid cancer. In addition to the 
thyroid, ¹³¹I accumulates in the salivary glands, giving rise to transient or permanent salivary 
gland damage. Salivary gland dysfunction following radioiodine therapy can be caused by 
radiation damage. But, it also may be associated with Sjögren syndrome (SS) developed after 
radioiodine therapy. It would be recommended that the evaluation for SS including anti-SSA/
Ro and anti-SSB/La should be considered before and after radioiodine therapy.
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INTRODUCTION
Sjögren syndrome (SS), the second most common auto-
immune rheumatic disease, refers to keratoconjunctivitis 
sicca and xerostomia resulting from immune lymphocytes 
that infiltrate the lacrimal and salivary glands. 
A significant number of SS patients complaining of 
symptoms, such as dryness of mouth, dryness of eyes, pain 
in the parotid region, altered taste, dental caries due to re-
duced salivation and difficulty in swallowing have been 
described.1) Patients with SS are also accompanied by sys-
temic problems, such as lymphoma and interstitial pneumo-
nia. Decreased saliva secretion may significantly reduce the 
quality of life of the patient.2)
Decreased saliva secretion may also be caused by radio-
iodine (131I) therapy.3,4) Salivary and lacrimal gland dysfunc-
tion is relatively frequent after radioiodine therapy. In most 
cases this is a transient side effect, but in some patients it 
may persist for a long period or appear late.3) 
Radioiodine therapy is often administered to patients fol-
lowing total thyroidectomy to treat well-differentiated fol-
licular cell-derived thyroid cancer. Radioiodine is an effec-
tive treatment for differentiated thyroid carcinomas after 
surgery. In addition to the thyroid, 131I accumulates in the 
salivary glands, giving rise to transient or permanent sali-
vary gland damage. Radioiodine secondarily targets the 
salivary glands where it is concentrated and secreted in the 
saliva 50-100 times to that found in serum.5-8) The parotid 
glands have proven to be more susceptible to the develop-
ment of radiation sialadenitis than the submandibular.1,9)
There are studies on the possibility of the occurrence of 
SS after radioiodine therapy for thyroid cancer.3) Thus, we 
present the case of a patient who was diagnosed with SS 
after radioiodine therapy for thyroid cancer. 
CASE REPORT
A 53-year-old woman presented with dry mouth and 
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abnormal taste. She had her thyroid gland removed surgi-
cally and received radioiodine therapy. The symptoms de-
veloped after radioiodine therapy. She also presented with 
dry eye after radioiodine therapy. 
Thus, the evaluation for SS including salivary flow test 
and laboratory test, such as anti-SSA/Ro and anti-SSB/La 
was done. 
An unstimulated whole salivary flow rate was 0.166 mL/
min and stimulated whole salivary flow rate by chewing 
gum base was 0.95 mL/min. Laboratory tests revealed that 
anti-SSA/Ro and anti-SSB/La were positive. And the sali-
vary gland scintigraphy showed a slightly reduced uptake 
in the parotid gland (Fig. 1). The Schirmer’s test was per-
formed for 5 minutes on the ophthalmologic examination 
and the result was 3 mm in the right eye and 4 mm in the 
left eye. Finally, she was diagnosed with SS.
According to the American European Consensus Group 
(AECG) criteria10) published in 2002, she had symptoms 
of dry eyes and dry mouth for at least 3 months, abnor-
mal Schirmer’s test result, decreased unstimulated whole 
salivary flow rate, abnormal salivary gland scintigraphy, 
and positive anti-SSA/Ro and anti-SSB/La. According to 
the American College of Rheumatology/European League 
Against Rheumatism (ACR/EULAR) classification criteria-ap-
proved classification criteria11,12) published in 2016, she had 
a total score of 4, derived from the sum of the weights as-
signed to anti-SSA/Ro and Schimer’s test. Her test results 
met both criteria for SS.
DISCUSSION
Radioiodine (131I) secondarily targets the salivary glands 
causing considerable radiation damage to these glands re-
sulting in xerostomia, pain, swelling, altered taste and 
dysphagia.5-7,13,14)
The radiation damage causes glandular inflammatory in-
filtration and concomitant swelling which may lead to an 
increased periductal pressure with subsequent ductal con-
striction.9,15,16) In addition, long-term effects on the lacri-

























































Fig. 1. Salivary scan of a 53-year-old woman 
was taken. Tc-99m pertech netate was 
in jected to the patient intra venously. Dy-
namic images of the sali vary glands were 
obtained before and after the gustatory 
stimulation. Uptake to the parotid glands 
is slightly decreased. RP, right parotid 
gland; RSM, right submandibular gland; 
LSM, left submandibular gland; LP, left 
parotid gland.
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ocular dryness and in some cases, nasolacrimal duct ob-
struction.7) Schirmer’s tear test was found to be abnormal in 
the patient after radioiodine therapy17) as 131I is excreted in 
tears and actively accumulated in the nasolacrimal duct.18) 
Obstruction of the lacrimal drainage system could occur af-
ter high-dose radioiodine therapy.19) 
The main symptom of the patient in this case was xe-
rostomia and abnormal Schirmer’s test was documented. 
There was associated xerostomia and impaired salivary 
function parameters which is in accordance with the find-
ing of Solans et al.1)
The patient complained of dry mouth after radioiodine 
therapy for thyroid cancer, and eventually was diagnosed 
with SS. Salivary gland dysfunction can be caused by ra-
diation damage. But, it also may be associated with SS de-
veloped after radioiodine therapy. The patient may already 
have SS prior to radioiodine therapy, but it is possible that 
radioiodine (131I) therapy treatment may have caused SS.
One study3) showed that SS may occur after radioiodine 
therapy for thyroid cancer. They reported that anti-SSA/Ro 
and anti-SSB/La after treatment was significantly increased 
compared with before radioiodine therapy, and 8 patients 
(25.81%) fulfilled the AECG criteria11) of classification of 
primary SS after radioiodine therapy. 
Patients receiving radiation iodine therapy should be con-
tinuously assessed for salivary glands and lacrimal glands. 
In conclusion, it would be recommended that the evalua-
tion for SS including anti-SSA/Ro and anti-SSB/La should 
be considered before and after radioiodine therapy in pa-
tients who plan to undergo radioiodine therapy.
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